NDAORALCAPSULE
Approved
Jun 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
BRUKINSA (zanubrutinib) by BeOne Medicines is bruton's tyrosine kinase inhibitors [moa]. First approved in 2025.
Drug data last refreshed 4h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BRUKINSA (zanubrutinib) is an oral Bruton's Tyrosine Kinase (BTK) inhibitor developed by BeOne Medicines that selectively targets BTK to treat B-cell malignancies and immune disorders. The drug works by blocking BTK signaling, which is critical for B-cell survival and proliferation. It represents a next-generation approach within the BTK inhibitor class with improved selectivity and tolerability profiles.
$0.8BPart D
Launch16.5 years to LOERecently launched product with established market presence ($801M Medicare Part D spending in 2023) signals an active commercial infrastructure and expanding team needs across sales, marketing, and market access functions.
Mechanism of Action
Bruton's Tyrosine Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
Started Dec 2026
40 enrolled
Chronic Lymphocytic Leukemia
Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Started Dec 2026
95 enrolled
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Started Oct 2026
155 enrolled
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
Started Jun 2026
40 enrolled
Mantle Cell Lymphoma
Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL：Stop Trial 2.0
Started Jun 2026
60 enrolled
CLL / SLL
Worked on BRUKINSA at BeOne Medicines? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.